Targeting Alpha7 Nicotinic Acetylcholine Receptors in Lung Cancer: Insights, Challenges, and Therapeutic Strategies
Issued Date
2024-01-12
Resource Type
eISSN
25759108
Scopus ID
2-s2.0-85181050499
Journal Title
ACS Pharmacology and Translational Science
Volume
7
Issue
1
Start Page
28
End Page
41
Rights Holder(s)
SCOPUS
Bibliographic Citation
ACS Pharmacology and Translational Science Vol.7 No.1 (2024) , 28-41
Suggested Citation
Arunrungvichian K., Vajragupta O., Hayakawa Y., Pongrakhananon V. Targeting Alpha7 Nicotinic Acetylcholine Receptors in Lung Cancer: Insights, Challenges, and Therapeutic Strategies. ACS Pharmacology and Translational Science Vol.7 No.1 (2024) , 28-41. 41. doi:10.1021/acsptsci.3c00138 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/95827
Title
Targeting Alpha7 Nicotinic Acetylcholine Receptors in Lung Cancer: Insights, Challenges, and Therapeutic Strategies
Author's Affiliation
Corresponding Author(s)
Other Contributor(s)
Abstract
Alpha7 nicotinic acetylcholine receptor (α7 nAChR) is an ion-gated calcium channel that plays a significant role in various aspects of cancer pathogenesis, particularly in lung cancer. Preclinical studies have elucidated the molecular mechanism underlying α7 nAChR-associated lung cancer proliferation, chemotherapy resistance, and metastasis. Understanding and targeting this mechanism are crucial for developing therapeutic interventions aimed at disrupting α7 nAChR-mediated cancer progression and improving treatment outcomes. Drug research and discovery have determined natural compounds and synthesized chemical antagonists that specifically target α7 nAChR. However, approved α7 nAChR antagonists for clinical use are lacking, primarily due to challenges related to achieving the desired selectivity, efficacy, and safety profiles required for effective therapeutic intervention. This comprehensive review provided insights into the molecular mechanisms associated with α7 nAChR and its role in cancer progression, particularly in lung cancer. Furthermore, it presents an update on recent evidence about α7 nAChR antagonists and addresses the challenges encountered in drug research and discovery in this field.